Biomedicine / 交易背景
AL050 licensing separates upfront cash from milestones
Background: Alector’s October 5 agreement gives Genentech exclusive worldwide AL050 development and commercialization rights: $100 million upfront, up to $1.17 billion in conditional milestones, plus sales royalties. The maximum is not cash already received.
The investigational program combines engineered GCase with brain delivery technology to address an enzyme deficiency associated with Parkinson’s disease. Genentech takes development, regulatory, manufacturing and commercial responsibilities; Alector keeps its delivery platform.
The program is moving toward clinical development, not an approved treatment with demonstrated human efficacy. Later payments depend on successful milestones.
Sources and further reading
主编加工
Selected through a verified followed account: @FierceBiotech.